Reformulating the fatty acid composition of foods to shift the fatty acid balance from saturated toward unsaturated species could redirect the hepatic lipid metabolism from synthesis to oxidation, reducing the production of ApoB-containing lipoproteins in the liver and complementing pharmacological therapies for atherogenic dyslipidemia. The gene discussed is APOB; the disease is metabolic syndrome.